J Breast Cancer.  2013 Mar;16(1):131-131.

If Progesterone Is Blamed for Breast Cancer Development, Why Are We Still Using Tamoxifen?

• Ozkaya E
• Korkmaz V
• Kucukozkan T
• Kara F

Abstract

No abstract available.

MeSH Terms

Breast
Breast Neoplasms
Progesterone
Progesterone

Reference

1. Gleason MX, Mdzinarishvili T, Sherman S. Breast cancer incidence in black and white women stratified by estrogen and progesterone receptor statuses. PLoS One. 2012. 7:e49359.

2. Yang LH, Tseng HS, Lin C, Chen LS, Chen ST, Kuo SJ, et al. Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer. 2012. 15:288–295.

3. Mackey RH, Fanelli TJ, Modugno F, Cauley JA, McTigue KM, Brooks MM, et al. Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women’s Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev. 2012. 21:2022–2032.

4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.

5. Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer. 1997. 79:494–499.

6. Strom BL, Berlin JA, Weber AL, Norman SA, Bernstein L, Burkman RT, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception. 2004. 69:353–360.

7. Engman M, Skoog L, Söderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008. 23:2072–2079.